Interesting.
A new ovarian cell creation process is developed by this Japanese company Dioseve and they can skip clinical trials because the product is not considered a medicine.
This new technology can reduce more than 80% of hormone injection in an IVF process.
Link to exact point of that conversation.
https://pca.st/episode/27b147a5-1d4e-4ed5-8464-a44b07279b69?t=1179.0
#biotech
#ivf
#fertility
#Dioseve
Tony 💉x11 🇦🇺
npub1gk…y24hd
2025-08-19 23:27:38 UTC
Author Public Key
npub1gk6xlf7ahdnnfezvzl5hfmg2qwghyq6kgjpwkuf56wjrjxc29xdq6y24hdSeen on
wss://relay.momostr.pinkPublished at
2025-08-19 23:27:38 UTCEvent JSON
{
"id": "61baf68a36e48b0fa1c6d5566eea9f148b642d8a5e4709b56ce3a11d248eb25e",
"pubkey": "45b46fa7ddbb6734e44c17e974ed0a03917203564482eb7134d3a4391b0a299a",
"created_at": 1755646058,
"kind": 1,
"tags": [
[
"t",
"fertility"
],
[
"t",
"dioseve"
],
[
"t",
"biotech"
],
[
"t",
"ivf"
],
[
"proxy",
"https://masto.ai/@kongakong/115058020059277060",
"web"
],
[
"proxy",
"https://masto.ai/users/kongakong/statuses/115058020059277060",
"activitypub"
],
[
"L",
"pink.momostr"
],
[
"l",
"pink.momostr.activitypub:https://masto.ai/users/kongakong/statuses/115058020059277060",
"pink.momostr"
],
[
"-"
]
],
"content": "Interesting. \n\nA new ovarian cell creation process is developed by this Japanese company Dioseve and they can skip clinical trials because the product is not considered a medicine.\n\nThis new technology can reduce more than 80% of hormone injection in an IVF process.\n\nLink to exact point of that conversation.\n\nhttps://pca.st/episode/27b147a5-1d4e-4ed5-8464-a44b07279b69?t=1179.0\n\n#biotech\n#ivf\n#fertility \n#Dioseve",
"sig": "55edc2fd4a26c56a91625a2ee94aa1ed8dbfdf7d080538ef2b86a0747bf08c7b008d0e715e8544b4601ce60fb640df84e4ab62665b2b0ab805b2c6baf07a5ac9"
}